AlphaMa and Viva Biotech Reached Cooperation Agreement on IntelligentDEL (iDEL) Screening Platform
AlphaMa will cooperate with Viva Biotech to provide clients AI-based DNA Encoded compound library screening technology.
SHANGHAI, CHINA—-Recently, AlphaMa Biotech signed a new drug discovery technology cooperation agreement with Viva Biotech Co., Ltd. (hereinafter referred to as ” Viva”). According to the agreement, AlphaMa will cooperate with Viva Biotech on innovative drug discovery technology to provide clients with the new generation of AI-based DNA Encoded compound library (Intelligent DEL, iDEL) screening technology platform for screening tumors and lead compounds for a series of specific targets in the field of neurological, autoimmune and other diseases.
RECOMMENDED ARTICLE
-
Alphama PatMap patent analysis platform is online!
-
PatMap patent analysis software has been launched
-
Simcere Pharmaceuticals and AlphaMa Biotech signed an exclusive license agreement for the new anti-tumor drug ALM005
-
AlphaMa and Lilly Collaborate on Drug Discovery Based on Intelligent DNA-Encoded Libraries
-
AlphaMa & SIMM Joint Team Won the Champion of the International Molecular Translation Challenge